<DOC>
	<DOCNO>NCT00004066</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combine gemcitabine , docetaxel , filgrastim treat patient recurrent persistent leiomyosarcoma soft tissue sarcoma remove surgery .</brief_summary>
	<brief_title>Gemcitabine , Docetaxel , Filgrastim Treating Patients With Recurrent Persistent Leiomyosarcoma Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate activity gemcitabine plus docetaxel administer filgrastim ( G-CSF ) support , term disease response , patient recurrent persistent unresectable leiomyosarcoma soft tissue sarcoma . - Determine tolerability regimen patient . - Correlate response tumor expression apoptosis-regulating protein bax , bcl-2 , survivin patient . OUTLINE : Patients stratify accord prior radiotherapy pelvis ( yes v ) . Patients receive gemcitabine IV 90 minute day 1 8 follow docetaxel IV 1 hour day 8 filgrastim ( G-CSF ) subcutaneously day 9-15 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients partial response may receive 2 additional course therapy . Patients follow every 3 month 1 year disease progression . PROJECTED ACCRUAL : A total 38-82 patient ( 19-43 uterine leiomyosarcoma 19-39 soft tissue sarcoma ) accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm leiomyosarcoma ( LMS ) soft tissue sarcoma No gastrointestinal stromal tumor , chondrosarcoma , Kaposi 's sarcoma , Ewing 's sarcoma , osteosarcoma , mesothelioma Recurrent progressive disease define increase size exist tumor ( development new tumor ) amenable definitive surgical therapy No prior chemotherapy OR Failed 2 prior chemotherapy regimen LMS uterus soft tissue sarcoma Bidimensionally measurable disease physical examination medical image technique Ascites pleural effusion consider measurable disease No uncontrolled CNS metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL Other : No active uncontrolled infection No prior malignancy except nonmetastatic squamous cell basal cell skin cancer noninvasive carcinoma situ cervix No history grade 3 4 peripheral neuropathy Not pregnant nurse PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy No prior gemcitabine docetaxel Endocrine therapy : Not specify Radiotherapy : At least 6 week since prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>